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Abstract
Tuberculosis (TB) is caused by Mycobacterium tuberculosis (Mtb). Bacille Calmette-Guérin (BCG) is the only licensed
vaccine against TB, and it is effective in children but not in adults. The Vaccine Research Team, Department of Microbiology FKUI has developed a DNA-based TB vaccine candidate pcDNA3.1-rpfB. This candidate induces immune responses in mice, but its potency is unknown. The gold standard for potency testing of TB vaccine is the challenge method.
The BSL3 animal laboratory for the challenge method is currently unavailable at FKUI. Therefore, mycobacterial growth
inhibition assay (MGIA) was used as a preliminary test before the in vivo challenge test was conducted. The principle of
MGIA is to reculture Mtb in a Mycobacteria Growth Indicator Tube (MGIT TM) from co-cultured Mtb with mammalian
cells that have been previously treated with pcDNA3.1-rpfB, pcDNA3.1 (negative control), and BCG (positive control).
MGITTM shows the time to positivity, which is the time that has lapsed until a positive growth of Mtb is detected. In
addition, measurements of interferon (IFN)γ levels by enzyme-linked immunosorbent assay were carried out. This study
concluded that pcDNA3.1-rpfB can inhibit the growth of Mtb in vitro and showed no statistical difference from BCG. The
IFNγ levels from co-culturing did not correlate with the level of inhibition of the growth of Mtb in vitro.
Keywords: mycobacterial growth inhibition assay (MGIA), Mycobacterium tuberculosis, resuscitation-promoting factor
B (rpfB), vaccine

the Vaccine Research Team of the Department of Microbiology, FKUI [6]. This pcDNA3.1-rpfB was constructed
from vector plasmid pcDNA3.1 of Escherichia coli
strain DHα and resuscitation-promoting factor B (rpfB)
genes obtained from the Beijing strain of Mtb genome.
This recombinant pcDNA3.1-rpfB plasmid successfully
induced humoral immune response, which is characterized by the formation of anti-RpfB antibodies confirmed
by Western blot, it can also express RpfB protein in mammalian cells (CHO-K1 cells) as evidenced by immunostaining, and stimulate cellular immune responses
in the form of T cell proliferation and interferon (IFN)γ
production [6, 7]. However, the efficacy of the
pcDNA3.1-rpfB TB vaccine candidate is unknown because no measurement of its efficacy in inhibiting Mtb
growth has been measured either in vivo or in vitro.

Introduction
Tuberculosis (TB) is an infectious disease caused by
Mycobacterium tuberculosis (Mtb). TB is one of the ten
diseases that caused the most death in the world in 2020.
Globally, an estimated 10 million people suffer from TB,
and 1.3 million of them die in 2020 [1]. According to
the data from the Ministry of Health of the Republic of
Indonesia, Indonesia has an estimated 845,000 cases TB,
and 13,947 of them died in 2020 [2].
Bacille Calmette-Guérin (BCG) is the only licensed
vaccine that is currently most available and used against
TB in the world. BCG comes from an attenuated virulent
strain of Mycobacterium bovis. This vaccine can prevent
TB in children but not in adults [3]. With the World
Health Organization’s (WHO) goal to eradicate TB by
2035, development of a new vaccine that is better than
BCG is crucial and is a component of the strategy to fight
the TB epidemic [3, 4, 5].

The widely used method for efficacy testing of TB
vaccine candidates is the challenge test through the
inhalation of Mtb by mice [8]. The challenge process
requires a high level of laboratory biosafety with special
equipment for the inhalation of Mtb by mice. This facility
is currently unavailable at the FKUI Microbiology

The development of pcDNA3.1-rpfB as a TB vaccine
candidate in the form of DNA vaccine was carried out by
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Laboratory. Therefore, in this study, the mycobacterial
growth inhibition assay (MGIA) was developed as a
preliminary test to measure the potency of TB vaccine
candidate pcDNA3.1-rpfB in inhibiting Mtb growth in
vitro.
In general, the MGIA involved the co-culture of
mammalian cells with Mtb within a certain time. The
mammalian cells used in this study were mouse splenocytes and peripheral blood mononuclear cells (PBMCs)
that had previously been immunized with the pcDNA3.1rpfB vaccine seed and then compared with the positive
(BCG vaccine) and negative (pcDNA3.1 only) controls. After co-culturing, Mtb was recultured in the Mycobacteria
Growth Indicator Tube (MGITTM) system. This system
provides a time to positivity (TTP) value, which is the
time from the beginning of culture to the occurrence of
positive fluorescence in the MGITTM [9]. The pcDNA3.1rpfB and BCG groups were expected to have a higher TTP
value than the negative control.

Materials and Methods
Research location and ethics: The research was conducted
at the Microbiology Laboratory, Faculty of Medicine,
Universitas Indonesia and approved by the Health Research
Ethics Committee of the Faculty of Medicine through the
Certificate of Passing the Ethics Review No. KET-1020/
UN2.F1/ETIK/PPM.00.02/2020.
Primers and plasmid: The primers and pcDNA3.1-rpfB
used in this study were designed and constructed accordance with our previous research [6]. Given the patent
purpose, we did not include the sequence of primers in
this report. Meanwhile, pCDNA3.1 was obtained from
the stock of the Department of Microbiology, Medical
Faculty, Universitas Indonesia.
Isolation of pcDNA3.1-rpfB and pcDNA3.1: Recombinant plasmid pcDNA3.1-rpfB and plasmid pcDNA3.1
were isolated from a suspension of E. coli DH5α. Stock
colonies of E. coli DH5α carrying the recombinant plasmid pcDNA3.1-rpfB and E. coli DH5α carrying
pcDNA3.1 were obtained, and each was cultured in 500
mL liquid LB containing 0.1 g/mL ampicillin and then
incubated in a shaker incubator at 200 rpm and 37 °C for
20 h. The bacterial suspension was then centrifuged at
5,000 rpm for 10 min. Plasmids were isolated from the
pellets formed, in accordance with the procedure listed in
the Hispeed Plasmid Midi Kit (QIAGEN).
Confirmation of rpfB gene by polymerase chain reaction
(PCR): To ensure that the rpfB gene was built in the recombinant plasmid pcDNA3.1-rpfB, we confirmed the
plasmid isolation by PCR. For this purpose, a forward
rpfB (F_rpfB) primer and a reverse rpfB (R_rpfB) primer
were used. In addition, PCR was carried out to verify the
correct direction of gene insertion using a forward CMV
Makara J. Sci.

(F_CMV) and a R_rpfB primers. PCR was conducted under an initial denaturation at 95 °C for 5 min, denaturation at 95 °C for 30 s, annealing at 55 °C for 30 s, elongation at 72 °C for 30 s, final elongation at 72 °C for 7
min, and final temperature at 25 °C with a total of 40 cycles.
Mouse immunizations: The animals used for this study
were BALB/c mice aged 6-8 weeks. The mice were randomly divided into three groups: (1) one group immunized with 100 µg/100 µL TB vaccine candidate
pcDNA3.1-rpfB intramuscularly, (2) one group injected
intramuscularly with 100 µg/100 µL pcDNA3.1 as the
negative control, and (3) one group immunized intraperitoneally with 100 µL BCG vaccine (Serum Institute
of India) as the positive control. After the first injection,
a booster was performed on days 14 and 28. One week
after the last booster, the mice were terminated, blood was
obtained from the heart, and the spleen was isolated.
Isolation of mouse splenocytes: Mouse spleen was isolated aseptically, and the splenocytes were extracted using Roswell Park Memorial Institute (RPMI) medium
containing L-glutamine and 10% fetal bovine serum
(RPMI-Sp). This process was carried out until the spleen
appeared transparent. Afterward, the splenocytes were
counted with a Neubauer counting chamber, and a splenocyte suspension was prepared with a final concentration of 3 x 106 cells in a total volume of 600 L RPMISp.
Mouse PBMCs and serum isolation: To obtain PBMCs,
we obtained ±1 mL of mouse blood from the heart aseptically using a 1 mL disposable tuberculin syringe and
collected it in an ethylenediaminetetraacetic acid tube.
Then, ±0.5 mL blood was obtained again aseptically for
serum isolation. The PBMCs were separated by histopaque-1077. Afterward, the PBMCs were counted using a Neubauer counting chamber, and a PBMC suspension with a final concentration of 3 x 10 6 cells was
prepared in a total volume of 600 L RPMI medium containing L-glutamine and 25 mM Hepes (RPMI-Pb). For
serum separation, ±0.5 mL blood in a centrifuge tube was
centrifuged at 10,000 rpm for 10 min. The supernatant,
which was the serum, was then separated.
MGIA: For the Mtb–splenocyte co-culture, 300 µL
splenocyte suspension was placed in the wells of a sterile
48-well plate and added with 300 µL 0.0005 McFarland
(McF) Mtb suspension. For the control of mammalian
cells, splenocyte suspension was added to the well with a
final concentration of 3 x 106 cells in 600 µL RPMI-Sp
without the addition of Mtb suspension. For bacterial
control, 300 µL Mtb 0.0005 McF and 300 µL RPMI-Sp
suspension were added to the wells without the addition
of splenocyte suspension. For the Mtb–PBMC co-culture,
270 µL PBMC suspension and 30 µL autologous serum
were placed in the wells of a sterile 48-well plate and
March 2022  Vol. 26  No. 1
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added with 300 µL 0.0005 McF Mtb suspension. For the
control of mammalian cells, PBMC suspension and
autologous serum were added to the wells at a final concentration of 3 x 106 cells in 600 µL RPMI-Pb without the
addition of Mtb suspension. For the bacterial control, 300
µL suspension of Mtb 0.0005 McF and 300 µL RPMI-Pb
were added without the addition of PBMCs and autologous
serum. The co-culture was incubated for 96 h at 37 °C
and 5% CO2. After 96 h, the co-culture samples were
transferred to a screw-cap centrifuge tube and centrifuged
at 12,000 rpm for 10 min to separate the Mtb. From the
supernatant formed, 300 µL was obtained and stored for
cytokine assay, whereas the pellet was resuspended with
the rest of the supernatant. A total of 300 µL resuspension
was cultured into the MGITTM unit and incubated in the
BACTECTM system until positive results were detected.
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significantly different (p = 0.828). The mean TTP of the
BCG group was higher and significantly different from
that of the pcDNA3.1 only group (p = 0.039). The
MGITTM showed that the control splenocytes in each
treatment group gave negative results.
Mtb reculture in MGITTM from Mtb–PBMC co-culture:
In the Mtb–PBMC co-culture, the MGITTM results
showed that the mean TTP of the pcDNA3.1-rpfB group
was 236.425 h, that of the pcDNA3.1 group (negative
control) was 213.783 h, and that of the BCG group
(positive control) was 239.456 h. To determine the
levelof significance between treatments, we statistically
analyzed the data using ANOVA followed by post-hoc
LSD test (Figure 3). Statistical analysis showed that the
mean value of TTP for the pcDNA3.1-rpfB group was

IFNγ level measurement using enzyme-linked immunosorbent assay (ELISA): The MGIA procedure above involved a storage step of 300 µL co-culture supernatant
for cytokine testing. The cytokine testing carried out on
these samples was the measurement of IFNγ levels by
ELISA. The ELISA steps were performed in accordance
with the procedures listed in the ELISA Kit. Absorbance
was measured by an ELISA reader at 450 nm.

Results
Confirmation of rpfB gene by PCR: Based on the results
of electrophoresis (Figure 1), the amplicon bands of the
rpfB gene, amplified with primers F_rpfB and R_rpfB
and with primers F_CMV and R_rpfB, were between the
1,000 and 1,500 bp marker bands, respectively.
This finding indicates the isolated recombinant plasmid
contained the rpfB gene. This result can be ascertained
because with primers F_rpfB and R_rpfB, the rpfB gene
was 1,089 bp, which corresponds to the size of the rpfB
gene itself [6, 7]. In addition, with primers F_CMV and
R_rpfB, the rpfB gene was about 1,100 bp because of the
additional length of the EcoR1 restriction site (6 bp),
HindIII restriction site (6 bp), and Kozak sequence (9 bp)
[6].
Mtb reculture in MGITTM from Mtb-splenocytes coculture: In the Mtb-splenocyte co-culture, the MGITTM
results showed that the mean TTP values of the
pcDNA3.1-rpfB group was 140.028 h, that of the
pcDNA3.1 group (negative control) was 138.787 h, and
that of the BCG group (positive control) was 151.770 h.
To determine the level of significance between
treatments, we analyzed the data statistically using
analysis of variance (ANOVA), followed-up by post-hoc
least significant difference (LSD) test (Figure 2).
Statistical analysis showed that the mean TTP of the
pcDNA3.1-rpfB group was not significantly different
from that of the BCG group (p = 0.057), and it was higher
than that of the pcDNA3.1 only group, although not
Makara J. Sci.

Figure 1. Electrophoresis Results of PCR Product of rpfB
Gene

(Note: * = not significantly different, ** = significantly
different)
Figure 2. Statistical Test Results of TTP Values from Mtb–
splenocytes Co-culture

not significantly different from that of the BCG group (p
= 0.769) but significantly higher than that of the
March 2022  Vol. 26  No. 1
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pcDNA3.1 group (p = 0.041). The MGITTM showed that
the PBMC control in each treatment group gave negative
results.

a significant difference was identified between pcDNA3.1
and BCG groups and their control PBMCs, with both
showing a significant difference at p = 0.000.

IFNγ levels from Mtb–splenocytes co-culture: The
ELISA showed that the mean value of IFNγ levels in the
pcDNA3.1-rpfB group was 1.424 pg/mL, that of the
pcDNA3.1 group was 1.377 pg/mL, and that of the BCG
group was 1.613 pg/mL. ANOVA was carried out to
determine the level of significance between treatments
(Figure 4). No significant difference was observed
between the mean IFNγ levels of each treatment group (p
= 0.788). T-test was performed to determine the level of
significance between each treatment with its splenocyte
control. Each treatment had a mean IFNγ level that was
significantly different from that of the splenocyte control.
The mean level of IFNγ in the pcDNA3.1-rpfB group was
significantly different from that of the control
splenocytes (p = 0.007). For the pcDNA3.1 and BCG
groups, the mean level of IFNγ were significantly
different from that of the control splenocytes (p = 0.000).

Correlation between TTP values and IFNγ levels: The
results of the MGITTM were in the form of TTP values
and those of ELISA in the form of IFNγ levels. Each
value was obtained from the results of Mtb-mammalian
cell co-culture and analyzed for statistical correlation.
Pearson correlation test showed no correlation between
the TTP values and IFNγ levels in the Mtb–splenocytes
(p = 0.911) and Mtb–PBMC (p = 0.648) co-cultures. This
result indicates that the level of IFNγ is not directly
correlated with the inhibition of Mtb growth in vitro
based on the TTP value.

IFNγ levels from Mtb–PBMC co-culture: The ELISA
showed that the mean IFNγ levels in the pcDNA3.1-rpfB,
pcDNA3.1, and BCG groups were 3.859 pg/mL, 4.035
pg/mL, and 4.742 pg/mL, respectively. Kruskal-Wallis
test was carried out to determine the level of significance
between treatments (Figure 5). No significant difference
was observed between the mean IFNγ level of each
treatment group (p = 0.440). T-test was performed to
determine the level of significance between each treatment
and its PBMC control. No significant difference was
noticed between the mean IFNγ levels in the pcDNA3.1rpfB group and the control PBMCs (p = 0.429). However,

(Note: * = not significantly different)
Figure 4. Statistical Test Results of IFNγ Levels from Mtb–
splenocytes Co-culture

(Note: * = not significantly different, ** = significantly
different)
Figure 3. Statistical Test Results of TTP Values from Mtb–
PBMC Co-culture

(Note: * = not significantly different)
Figure 5. Statistical Test Results of IFNγ Levels from Mt –
PBMC Co-culture
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Discussion
This pcDNA3.1-rpfB TB vaccine candidate was
developed in the form of a DNA vaccine because this
type has numerous advantages. DNA vaccines can trigger
an immune response involving B and T cells. In addition,
this vaccine contains no live components. Thus, the risk
of disease caused by the vaccine is zero. The
development of DNA vaccine is relatively easy and
inexpensive. DNA vaccines do not require special
facilities for storage, unlike RNA vaccines which require
very cold storage conditions [10].
Various studies mentioned that BCG is effective in
preventing TB in children but not in adults. BCG can
provide protection against Mtb because it induces the
response of T helper 1 (Th1) CD4 cells and CD8 cytotoxic
T cells [10]. A research proved that the induction of Th1
and Th17 cells is needed to form an ideal protection
against TB [11]. BCG can induce Th1 response but fails
to induce Th17 response in the lungs, which results in the
low efficiency of the BCG vaccine.
This pcDNA3.1-rpfB vaccine candidate is expected to
have better efficacy than BCG or as a companion to BCG
vaccine in building an immune response against Mtb
infection because the RpfB protein encoded by the rpfB
Mtb gene has the highest biological and immunological
characteristics among other proteins in the Rpf family [6,
7]. The RpfB protein is highly expressed during Mtb
resuscitation. Various studies have also shown that the
rpfB protein has an important role in Mtb replication in
vivo [12].
The mammalian cells used in this study were splenocytes
and PBMCs. Splenocytes were selected because they
consist of various populations of immune cells, such as T
lymphocytes, B lymphocytes, dendritic cells, and
macrophages that have different immune functions.
PBMC was selected because they consist of T
lymphocytes, B lymphocytes, natural killer cells, and
monocytes, which also play an important role in the
immune response of the body [13].
The BACTECTM MGITTM system was selected in this
MGIA because it has numerous advantages over
conventional Mtb culture systems. Mtb is categorized as
slow growth bacteria, with a doubling time of 10–20 h
[14, 15]. Thus, conventionally cultured Mtb can only be
detected positive in 5-8 weeks. This system can reduce
the time for obtaining test results to a matter of days. This
is achievable because each MGITTM unit contains
Middlebrook 7H9 liquid medium, PANTA antibiotic
blend, OADC growth supplement, and is equipped with
a fluorescence indicator. All of these conditions can
facilitate the Mtb culture to reach a concentration
equivalent to 105–106 colony forming units and allow the
detection of positive results. In addition, the BACTECTM
Makara J. Sci.
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MGITTM system is sensitive to detecting mycobacteria
and has a large incubation capacity [16].
The mean TTP value from the co-culture of Mtb–
splenocytes showed that splenocytes in the BCG group
had a higher potency for inhibiting Mtb growth in vitro
than the negative control. Splenocytes treated with the
TB vaccine candidate pcDNA3.1-rpfB had the potency
for inhibiting Mtb growth in vitro, which was not
different from the BCG group. On the other hand, the
mean TTP value from the Mtb–PBMC co-culture showed
that PBMCs in the pcDNA3.1-rpfB and BCG groups had
a higher potency for inhibiting Mtb growth in vitro than
the negative control. In addition, PBMCs in the
pcDNA3.1-rpfB TB vaccine candidate group had Mtb
growth inhibition potency in vitro, which is similar to that
of the BCG group.
From this MGIA study based on the TTP value, the Mtb–
splenocyte and Mtb–PBMC co-cultures gave similar
results. The results showed that the TB vaccine candidate
pcDNA-3.1-rpfB had Mtb growth inhibition potency in
vitro which is similar to that of the BCG vaccine. This
finding can be a good support for the further development
of the pcDNA3.1-rpfB TB vaccine candidate.
Marsay et al. [17] used MGIA to examine the inhibition
of Mtb growth by splenocytes of mice immunized with
BCG compared to naive controls. Parra et al. [18, 19] also
used MGIA to examine the inhibition of Mtb growth by
splenocytes of mice immunized with BCG compared to
naive controls and five novel vaccines. MGIA is a WHOsupported method for testing TB vaccine candidates. The
WHO's goal in supporting the MGIA is to develop
functional tests that can be applied to all TB vaccine
candidate clinical trials; thus, they can help in identifying
the correlation between potential TB vaccine candidates
and built-up immunity [20].
The levels of IFNγ in the supernatant from the co-culture
of Mtb and mammalian cells in this study were measured
by ELISA. This step was performed because IFNγ was
the dominant type of cytokine produced in vivo by
BaLB/c mice treated with pcDNA3.1-rpfB in the
previous study. The results of statistical analysis on the
average IFNγ level were not in line with the results of
statistical analysis of the average TTP value. However, if
further observed, the level of values was linear, with the
BCG group having the highest value and the pcDNA3.1
group having the lowest value. Each treatment group had
higher levels of IFNγ that were significantly different
from the control mammalian cells (splenocytes and
PBMCs). This results indicates that the addition of Mtb
suspension to splenocytes and PBMC co-cultures can
increase IFNγ production.
Statistical analysis was carried out to determine the
correlation between the TTP values and IFNγ levels in
March 2022  Vol. 26  No. 1
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the co-cultured Mtb and mammalian cells. Data from the
MGITTM test results in the form of TTP values and
ELISA data in the form of IFNγ levels were analyzed by
the Pearson correlation test. This test showed no
correlation between the TTP values and IFNγ levels in
the Mtb-splenocyte and Mtb-PBMC co-cultures. This
finding indicates that IFNγ levels are not directly
correlated with TTP values, that is, they are not directly
related to Mtb growth inhibition in vitro.
No statistical correlation existed between the TTP values
and IFNγ levels due to a complex immune response
system. After infection, Mtb stimulates CD4, CD8 T
cells, and other immune cells to secrete IFNγ, which
dominates the strong type-1 immune response. IFNγ then
plays a role in activating the bactericidal action in the
host cell. However, in addition of IFNγ, other cytokines,
such as interleukin 10 (IL-10), are present in the system.
In contrast to IFNγ, IL-10 is considered an inhibitory
cytokine. The presence of IL-10 is important for the
adequate balance between inflammatory and immunopathological responses. Elevated levels of IL-10 favor
mycobacterial survival in host cells [15]. Therefore,
given that other cytokines are counterproductive, this
condition may be the cause of the absence of a statistical
correlation between the TTP values and IFNγ levels.

Conclusion
This study revealed that the TB vaccine candidate
pcDNA3.1-rpfB has efficacy for inhibiting Mtb growth
in vitro, but it is not significantly different from that of
the BCG, according to the MGIA. IFNγ levels in cocultured Mtb and mammalian cells did not correlate with
the level of inhibition of Mtb growth in vitro.
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